George Washington University has collaborated with Moderna to test the safety of the first mRNA HIV vaccines and the immune responses of two participants in the Phase 1 clinical trial. Four institutions, including GW, have enrolled 56 HIV-negative adult participants for the vaccines’ clinical trials. The mRNA HIV vaccine aims to block the replication of HIV strains and stimulate the production of broadly neutralizing antibodies that control the virus within HIV-positive patients’ immune systems. Read more by clicking the link!
University administers first doses of mRNA HIV vaccine through Moderna partnership
Latest News
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
Latest news about the results of the COVAIL trial regarding the Sanofi booster. GW participated as one of the many sites for this COVID-19 vaccine study.